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Developing Confidence in Risk
Assessments Based on Physiological
Toxicokinetic Models
A physiologically based toxicokinetic model typically represents
the uptake ofa toxicant by a laboratory animal, its distribution to
various organs, its metabolic activation and/or detoxication, and
elimination ofthe parent compound and its metabolites. The aim
is to predict the dose response of the actual toxic agent (parent
compound or metabolite) in the tissue that ulti-
mately develops symptoms of toxicity. In many 1
cases, a subsequent response stimulated by the a
toxic agent may be mechanistically related to the
ultimate health outcome and can serve as an indi-
cator ofthe effects ofthe administered chemical. A
model can quantify this response as a function of
dose, permitting it to be used as a dose surrogate in
estimating the toxicant's effects at low exposures.
Because toxicokinetic modeling incorporates a
large amount of information about the animal
beyond the observation of the incidence of the
endpoint at various doses, it offers a method of
reducing the uncertainties in risk assessments based
solely on external exposure.
Although human physiology is qualitatively
similar to that of laboratory animals, the rates of g
some ofthe physiological and biochemical process-
es, and hence tissue dosimetry, differ quantitatively
among species. Two ofthe most difficult but criti-
cal problems in risk assessment are identifying 1
doses to humans that are equivalent to doses given
to laboratory animals and predicting the shape ofm
the dose-response curve at doses too low to yield a
response that can be distinguished from interindi- 1 i
vidual variability. If experimentally determined
parameter values for humans are available to
replace the corresponding values for a laboratory
animal in a validated dosimetric model, then the model could be
used to predict tissue dosimetry in humans. Including human
interindividual variability in the model could permit identifica-
tion ofsusceptible subpopulations. A mathematical model based
on physiological principles incorporates mechanisms thought to
relate dosimetry to toxicity, and it provides a stronger scientific
foundation for estimating equivalent doses across species, includ-
ing humans, than does the default method ofallometric scaling.
In order to develop confidence in biologically based risk
assessments, a model must provide a realistic representation of
the biological system and describe the relationship between expo-
sure to a chemical and responses leading to its toxic effects. For
example, in a realistic model of inhalation of a gas from an
enclosed chamber, inhaled material passes through the alveolar
space and lung capillary blood before mixing with the general cir-
culation. Simple models in which gas in the chamber equilibrates
directly with the entire blood volume produce an artificial dilu-
tion effect on dissolution ofthe gas in blood, leading to larger con-
centration gradients between inhaled air and blood and conse-
quently more rapid calculated gas uptake. Similarly, inclusion of
tissue capillary spaces in the model leads to smaller blood:tissue
gradients than do models which do not include this representation
of blood distribution. A realistic model would
"a lpge! predict greater activity of a metabolizing enzyme
in order to reproduce a given clearance rate than
would a model in which toxicant in the metabo-
lizing tissue equilibrates with the entire circula-
tion. Simplified models that consider all metabo-
lism of the toxicant to occur in the liver even
though the metabolizing enzyme is also known to
be expressed in other tissues may reproduce the
observed uptake of the toxicant because of the
overestimation of the rate of distribution via the
blood. Because the computed dosimetry is sensi-
tive to the mathematical description of lung and
7' blood physiology, predictions based on a realistic
! representation of anatomy would be expected to lmore closely reflect the true biological behavior.
Measurements of enzymatic activity and metabo-
; lite concentrations in various tissues could resolve
this ambiguity.
Toxicokinetic models can exhibit a curious
combination ofsensitivity to the values ofphysio-
logical and biochemical parameters and a lack of
mI~~k robustness. Measurements ofpartition coefficients
from different laboratories frequently differ by
factors of2-4; measured activities ofmetabolizing
_ enzymes in a given tissue may vary by an order of
m i~ magnitude. Significant differences in the fit of a
model to experimental data for uptake and clear-
ance often can be obtained by using different particular measured
values for one parameter while keeping other parameter values
fixed. However, there is usually a sufficient number of adjustable
parameters in a model to permit an adequate fit to limited data on
the biological fate ofthe toxicant. Parametervalues obtained by fit-
ting uptake data by formal optimization can vary considerably
depending on which measured value is included in the model. This
lack ofrobustness arises from the nonidentifiability ofthe parame-
ters owing to such a limited data set and could be avoided if
time-course data for blood and tissue concentrations of parent
compound and/or metabolite(s) were available. Ideally, time cours-
es of metabolic intermediates should be obtained for the same
experiments that provided the uptake and elimination data.
Validation of models requires that the model reproduce data
other than those used to estimate the model's parameters; other-
wise, the modeling procedure is merely an exercise in curve fitting.
For example, toxicokinetic models with differing levels of detail
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can give comparable fits to uptake data but make different predic-
tions for concentrations ofintermediates and metabolic cofactors.
Most models in which a toxicant is deared by conjugation with a
cofactor describe this enzyme by hyperbolic kinetics with respect
to the substrate but neglect both the binding ofthe cofactor and
its depletion by the chemical reaction. Ifparameters in such a sim-
plified model are estimated to reproduce only the rate ofuptake of
the chemical, the model may fail to reproduce the effect of the
chemical on cofactor concentration. Therefore, confirming that a
model fits data sets for different measures other than those used in
its construction permits discrimination among competing models.
There is a long sequence ofbiological events between delivery
of a toxicant to target tissues and the production ofthe ultimate
adverse health effect. These events might include mutagenicity
consequent to formation and misrepair of adducts with DNA
bases or altered expression of mitogenic proteins induced by a
complex between the toxicant and a transcription factor.
Toxicokinetic models almost never are extended to include such
events, thus leaving a gap between tissue dosimetry and the ulti-
mate response. Measurement ofsuch responses, for example, accu-
mulation ofDNA adducts or production ofinduced proteins, are
necessary to extend toxicokinetic models beyond dosimetry and
identify quantitative relationships between tissue dose of a toxi-
cant and those biomarkers. More realistic biologically based mod-
els would improve estimates ofsite-specific human dose responses
associated with riskofadverse health effects.
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T he Johns Hopkins Center forAlternatives toAnimal Testing (CAAT) would like to honor
and individual or organization who has made an outstanding contribution to the field of
3Rs alternatives and in vitro sciences. We invite the readers ofthis journal to submit nomina-
tions. The award will be presented at the secondWorld Congress onAlternatives andAnimal
Use in the Life Sciences,to be held in October 1996 in Utrecht,The Netherlands. Deadline for
receipt of nominations isJune I, 1996. Please send your nomination, including a one-page
description ofwhy this individual or organization should be recognized. Please include a cur-
riculum vitae for individual nominees and a fact sheet or supporting documents for organiza-
tions. A subcommittee ofthe CAATAdvisory board will review the nominations and select
the recipient ofthe CAAT RecognitionAward
Forward nominations to: Alan M. Goldberg, Ph.D.,Johns Hopkins Center forAlternatives
toAnimalTesting I I I Market Place,Suite 840, Baltimore, MD 21202-6709
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